0
Clinical Investigations: INFLAMMATORY LUNG DISEASE |

Combined Corticosteroid and Cyclophosphamide Therapy Does Not Alter Survival in Idiopathic Pulmonary Fibrosis*

Harold R. Collard, MD; Jay H. Ryu, MD, FCCP; William W. Douglas, MD; Marvin I. Schwarz, MD, FCCP; Douglas Curran-Everett, PhD; Talmadge E. King, Jr., MD, FCCP; Kevin K. Brown, MD, FCCP
Author and Funding Information

*From the Department of Medicine (Drs. Collard and Schwarz), Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO; Department of Internal Medicine (Drs. Ryu and Douglas), Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN; National Jewish Medical and Research Center (Dr. Brown), Denver, CO; Departments of Preventive Medicine and Biometrics (Dr. Curran-Everett), University of Colorado Health Sciences Center, Denver, CO; and Department of Medicine (Dr. King), San Francisco General Hospital, University of California at San Francisco, San Francisco, CA.

Correspondence to: Kevin K. Brown, MD, FCCP, 1400 Jackson St, Room F107, Denver, CO 80206; e-mail: brownk@njc.org



Chest. 2004;125(6):2169-2174. doi:10.1378/chest.125.6.2169
Text Size: A A A
Published online

Study objectives: Treatment of patients with idiopathic pulmonary fibrosis (IPF) conventionally includes corticosteroids and cytotoxic agents. No study to date has adequately evaluated the benefits of this approach. This study retrospectively compared combination corticosteroid and cyclophosphamide therapy in a large population of patients who meet the current consensus definition of IPF.

Design: Patients were identified retrospectively and treatment addressed on an intention-to-treat basis. Treated and untreated patients were matched by age and percentage of predicted FVC (FVC%) at the time of the initial visit.

Setting: Two academic tertiary referral centers.

Patients or participants: The diagnosis of IPF was based on current consensus criteria. A total of 164 patients (82 treated and 82 untreated) were included.

Interventions: Treatment consisted of combined corticosteroid and cyclophosphamide therapy using a standardized protocol.

Measurements and results: There was no difference in age, FVC%, gender, or smoking status between groups. No survival difference was found between patients who were treated (median survival, 1,431 days) or untreated (median survival, 1,665 days) [p = 0.58]. The lack of treatment effect persisted when only those patients with a diagnosis by surgical biopsy (n = 24) or FVC% ≥ 60 (n = 107) were analyzed.

Conclusions: Our data suggest that combined corticosteroid and cyclophosphamide therapy has no impact on survival in patients with IPF. This finding supports the evolving concept that chronic inflammation plays a minimal role in the progression of IPF and reinforces the importance of careful consideration of the risks and benefits of such therapies prior to their institution.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Guidelines
Focal segmental glomerulosclerosis: cytotoxic therapy.
Caring for Australasians with Renal Impairment | 7/10/2009
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543